APGNW - Apexigen Inc - Warrants (29/07/2027)
Close
0.0261
0.006 23.372%
Share volume: 0
Last Updated: Tue 22 Aug 2023 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.02
0.01
30.50%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-27.96%
1 Month
-24.72%
3 Months
-49.37%
6 Months
-82.05%
1 Year
-94.09%
2 Year
-97.88%
Key data
Stock price
$0.03
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.01 - $0.42
52 WEEK CHANGE
-$0.95
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website:
Employees: 29
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 29
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by apximab™, the company’s proprietary antibody drug discovery platform. its lead immuno-oncology drug candidate, apx005m, is a potent immune-activating antibody against cd40 currently in phase 2 clinical development.
Recent news